Sweroside pharmaceutical preparation and application thereof in prevention of tobacco mosaic virus

A technology of tobacco mosaic disease and swertigin, which is applied in the field of plant medicine and application, to achieve the effect of inhibiting TMV infection and using it safely and reliably

Active Publication Date: 2012-10-03
云南省农业科学院生物技术与种质资源研究所 +2
View PDF5 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most of the medicinal plants of this genus have the effects of clearing away heat and gallbladder, strengthening the heart, soothing the liver and invigorating the stomach, and detoxifying. They are used to treat diseases such as hepatitis, icteric hepatitis, and liver and gallbladder.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sweroside pharmaceutical preparation and application thereof in prevention of tobacco mosaic virus
  • Sweroside pharmaceutical preparation and application thereof in prevention of tobacco mosaic virus
  • Sweroside pharmaceutical preparation and application thereof in prevention of tobacco mosaic virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0034] The macroporous resin column is any one of D900, D130, D101, D201 or D301.

[0035] The semi-preparative column is any one of the Agel semi-preparative column, the HPLC semi-preparative column or the Japanese Weimeixi semi-preparative column. Purification is carried out on the Ajel semi-preparative column, and methanol / water solution is used for elution to obtain the swertigin compound.

[0036] The dosage form of the swertigin pharmaceutical preparation of the present invention is: the swertigin compound is mixed with non-toxic pharmaceutically acceptable adjuvants and / or excipients to humans and animals according to the ratio required by the formula, and prepared into water, tablets, etc. formulations, granules or microemulsions.

[0037] The pharmaceutical carrier or excipient is one or more solid, semi-solid and liquid diluents, fillers and pharmaceutical preparation adjuvants. Prepare various dosage forms by methods recognized in the fields of pharmacy and food, ...

Embodiment 1

[0040] Take the dry Southwestern Swertia japonica and grind it, extract it twice with 75% methanol, 1 hour each time; combine the extracts, filter and remove the slag, combine the filtrates, and then concentrate under reduced pressure to obtain an extract with a relative density of 1.2~1.3; the extract is added in 1 Double volume of water was stirred until it was suspended, extracted twice with 98% dichloromethane solution, each time for 15 min; the combined extracts were decolorized by MCI, and then eluted with 75% methanol, and the eluate was collected; Use a D900 macroporous resin column to remove sugar, elute with a solution of methanol / water (V / V) 10:90, collect the eluate; concentrate to obtain an extract, separate it by HPLC, and elute with 70% methanol aqueous solution. Finally, the Ajel semi-preparative column was purified, and eluted with 70% aqueous methanol to obtain the swertiin compound.

Embodiment 2

[0042]Take the shade-dried Southwest Swertia japonica, and extract it with 85% methanol for 3 times, each time for 3 hours; combine the extracts, filter and remove the slag, combine the filtrates, and then concentrate under reduced pressure to obtain an extract with a relative density of 1.2~1.3; the extract is added with 3 Double volume of water was stirred until it was suspended, and extracted with 95% dichloromethane solution for 3 times, each time for 25 minutes; the combined extracts were passed through an MCI column for decolorization, and then eluted with 70% methanol, and the eluate was collected; Then use a D130 macroporous resin column to remove sugar, elute with a solution of methanol / water (V / V) 30:70, collect the eluate; concentrate to obtain an extract, separate it by HPLC, and elute with 80% methanol aqueous solution. Finally, the HPLC semi-preparative column was used for purification, and was eluted with 80% methanol aqueous solution to obtain the swertigin comp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a sweroside pharmaceutical preparation and application thereof in prevention of a tobacco mosaic virus. The sweroside pharmaceutical preparation comprises 0.1-99% of sweroside and the balance pharmaceutic adjuvant and/excipient which is/are acceptable in pharmacology. The sweroside used in the sweroside pharmaceutical preparation can be separated and prepared from swertia cincta burk, the method is simple and the extraction rate is high. The sweroside pharmaceutical preparation has wide application prospects in prevention of the tobacco mosaic virus. The sweroside is separated and obtained from the swertia cincta burk through a modern separation technology. An experiment shows that the sweroside can significantly inhibit the tobacco mosaic virus (TMV) infection activity and serves as a novel plant virus resistance activity ingredient to be used for preventing a TMV disease, and the inhibition effect of the sweroside pharmaceutical preparation is better than that of other sold TMV resistant plant preparations (such as ningnanmycin). The sweroside pharmaceutical preparation is a pure biological agent, is harmless to people and animals, has a significant effect on TMV disease prevention and can be used in production of organic tobaccos.

Description

technical field [0001] The invention belongs to the technical field of herbal medicines and applications, and in particular relates to a pharmaceutical preparation of swertigin, obtained from Southwest Swertia japonica ( Swertia cincta Burk) method for extracting swertigin, and the application of pharmaceutical preparations in the preparation and prevention of tobacco mosaic virus disease and antiviral preparations. Background technique [0002] tobacco mosaic virus ( Tobacco mosaic virus , TMV) is the pathogen of tobacco mosaic disease, etc., and belongs to the Tobamovirus genus in the family Tobaviridae ( Tobamovirus ). TMV has a wide range of hosts and can infect more than 300 kinds of plants in 30 families. It is seriously harmful to food crops such as tobacco and tomato. The annual loss caused by mosaic disease caused by TMV in the world exceeds 100 million U.S. dollars. Agricultural production causes huge economic losses. However, because TMV is absolutely parasi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A01N43/90A01P1/00C07H17/04C07H1/08
Inventor 张仲凯莫笑晗陈永对董家红李干鹏胡剑余清张廷金
Owner 云南省农业科学院生物技术与种质资源研究所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap